GOODWILL AND OTHER INTANGIBLE ASSETS (Notes)

9 Months Ended

Jul. 31, 2023

Goodwill and Intangible Assets Disclosure [Abstract]

The following table presents goodwill balances and the movements for each of our reportable segments during the nine months ended July 31, 2023:


	Life Sciences and Applied Markets		Diagnostics and Genomics		Agilent CrossLab		Total
	(in millions)
Goodwill as of October 31, 2022	$	1,743	$	1,953	$	256	$	3,952
Foreign currency translation impact	11		1		5		17
Goodwill arising from acquisitions and adjustments	—		15		—		15
Goodwill as of July 31, 2023	$	1,754	$	1,969	$	261	$	3,984

The component parts of other intangible assets as of October 31, 2022 and July 31, 2023 are shown in the table below:


	Other Intangible Assets
	Gross Carrying Amount		Accumulated Amortization		Net Book Value
	(in millions)
As of October 31, 2022
Purchased technology	$	1,733	$	1,068	$	665
Trademark/Tradename	196		148		48
Customer relationships	180		105		75
Backlog	8		8		—
Third-party technology and licenses	32		9		23
Total amortizable intangible assets	2,149		1,338		811
In-Process R&D	10		—		10
Total	$	2,159	$	1,338	$	821
As of July 31, 2023
Purchased technology	$	1,470	$	1,078	$	392
Trademark/Tradename	196		159		37
Customer relationships	156		114		42

Third-party technology and licenses	33		12		21
Total amortizable intangible assets	1,855		1,363		492
In-Process R&D	10		—		10
Total	$	1,865	$	1,363	$	502

During the nine months ended July 31, 2023, we recorded additions of $15 million to goodwill and $49 million to other intangible assets in our diagnostics and genomics and life sciences and applied markets segments related to two acquisitions. During the nine months ended July 31, 2023, other intangible assets in total increased $3 million due to the impact of foreign currency translation.

In general, for U.S. federal tax purposes, goodwill from asset purchases is amortizable; however, any goodwill created as part of a stock acquisition is not deductible.

Each quarter we review the events and circumstances to determine if impairment of indefinite-lived intangible assets and goodwill is indicated. During the three and nine months ended July 31, 2023 and 2022 we did not identify any triggering events or circumstances which would indicate an impairment of goodwill or indefinite-lived intangible assets. During the three and nine months ended July 31, 2023, we recorded an impairment of finite-lived intangible assets of $258 million related to the shutdown of our Resolution Bioscience business in our diagnostics and genomics segment. Of the $258 million, $249 million was recorded in cost of sales and $9 million was recorded in selling, general and administrative expenses on our condensed consolidated statement of operations in both the three and nine months ended July 31, 2023.

Amortization expense of intangible assets was $39 million and $113 million for the three and nine months ended July 31, 2023, respectively. Amortization expense of intangible assets was $48 million and $150 million for the three and nine months ended July 31, 2022, respectively.

Future amortization expense related to existing finite-lived purchased intangible assets for the remainder of fiscal year 2023 and for each of the next five fiscal years and thereafter is estimated below:


Estimated future amortization expense:
(in millions)
Remainder of 2023	$	27
2024	$	100
2025	$	83
2026	$	53
2027	$	52
2028	$	45
Thereafter	$	132